Bioceres Crop Solutions Valuation
Is BIOX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOX ($6.46) is trading above our estimate of fair value ($3.48)
Significantly Below Fair Value: BIOX is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOX?
Key metric: As BIOX is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BIOX's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | US$441.23m |
| Market Cap | US$399.72m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 11.3x |
| PEG Ratio | 3.9x |
Price to Sales Ratio vs Peers
How does BIOX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
IPI Intrepid Potash | 1.6x | 3.9% | US$332.7m |
UAN CVR Partners | 1.4x | n/a | US$753.5m |
AVD American Vanguard | 0.3x | 4.8% | US$182.8m |
MULG Muliang Viagoo Technology | 4.1x | n/a | US$49.1m |
BIOX Bioceres Crop Solutions | 0.9x | 9.6% | US$399.7m |
Price-To-Sales vs Peers: BIOX is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (1.9x).
Price to Sales Ratio vs Industry
How does BIOX's PS Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Sales vs Industry: BIOX is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Chemicals industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is BIOX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | 1.4x |
Price-To-Sales vs Fair Ratio: BIOX is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$6.46 | US$12.13 +87.7% | 12.5% | US$13.00 | US$9.50 | n/a | 4 |
| Nov ’25 | US$6.49 | US$12.40 +91.1% | 9.7% | US$13.00 | US$10.00 | n/a | 5 |
| Oct ’25 | US$7.86 | US$13.50 +71.8% | 9.4% | US$16.00 | US$12.50 | n/a | 5 |
| Sep ’25 | US$10.64 | US$19.00 +78.6% | 18.8% | US$25.00 | US$15.00 | n/a | 5 |
| Aug ’25 | US$10.81 | US$19.00 +75.8% | 18.8% | US$25.00 | US$15.00 | n/a | 5 |
| Jul ’25 | US$11.13 | US$20.25 +81.9% | 15.4% | US$25.00 | US$17.00 | n/a | 4 |
| Jun ’25 | US$11.78 | US$20.25 +71.9% | 15.4% | US$25.00 | US$17.00 | n/a | 4 |
| May ’25 | US$11.66 | US$20.25 +73.7% | 15.4% | US$25.00 | US$17.00 | n/a | 4 |
| Apr ’25 | US$12.62 | US$20.25 +60.5% | 15.4% | US$25.00 | US$17.00 | n/a | 4 |
| Mar ’25 | US$13.36 | US$20.40 +52.7% | 13.7% | US$25.00 | US$17.00 | n/a | 5 |
| Feb ’25 | US$13.25 | US$21.20 +60.0% | 22.2% | US$28.00 | US$15.00 | n/a | 5 |
| Jan ’25 | US$13.73 | US$21.20 +54.4% | 22.2% | US$28.00 | US$15.00 | n/a | 5 |
| Dec ’24 | US$12.36 | US$21.20 +71.5% | 22.2% | US$28.00 | US$15.00 | n/a | 5 |
| Nov ’24 | US$10.36 | US$22.10 +113.3% | 20.1% | US$28.00 | US$15.00 | US$6.49 | 5 |
| Oct ’24 | US$11.29 | US$24.30 +115.2% | 22.4% | US$31.00 | US$15.00 | US$7.86 | 5 |
| Sep ’24 | US$12.06 | US$25.30 +109.8% | 23.4% | US$31.00 | US$15.00 | US$10.64 | 5 |
| Aug ’24 | US$12.71 | US$25.30 +99.1% | 23.4% | US$31.00 | US$15.00 | US$10.81 | 5 |
| Jul ’24 | US$13.36 | US$25.30 +89.4% | 23.4% | US$31.00 | US$15.00 | US$11.13 | 5 |
| Jun ’24 | US$12.20 | US$25.30 +107.4% | 23.4% | US$31.00 | US$15.00 | US$11.78 | 5 |
| May ’24 | US$11.17 | US$25.30 +126.5% | 23.4% | US$31.00 | US$15.00 | US$11.66 | 5 |
| Apr ’24 | US$11.61 | US$27.05 +133.0% | 12.5% | US$31.00 | US$22.50 | US$12.62 | 5 |
| Mar ’24 | US$11.50 | US$27.05 +135.2% | 12.5% | US$31.00 | US$22.50 | US$13.36 | 5 |
| Feb ’24 | US$12.49 | US$26.45 +111.8% | 10.7% | US$30.00 | US$22.50 | US$13.25 | 5 |
| Jan ’24 | US$12.03 | US$26.45 +119.9% | 10.7% | US$30.00 | US$22.50 | US$13.73 | 5 |
| Dec ’23 | US$13.41 | US$26.45 +97.2% | 10.7% | US$30.00 | US$22.50 | US$12.36 | 5 |
| Nov ’23 | US$14.42 | US$25.45 +76.5% | 8.8% | US$28.00 | US$22.50 | US$10.36 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Ecora Resources
UK£159.8m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
ECRA.F
UK£0.85
7D
10.4%
1Y
-22.7%
Huntsman
US$3.3b
Manufactures and sells diversified organic chemical products worldwide.
HUN
US$19.42
7D
-1.3%
1Y
-22.1%
Chemtrade Logistics Income Fund
CA$1.4b
Offers industrial chemicals and services in Canada, the United States, and South America.
CGIF.F
CA$8.20
7D
4.0%
1Y
30.0%